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Res Syn Meth. 2019;1–13.Background: Network meta‐analysis (NMA) is a powerful analysis method
used to identify the best treatments for a condition and is used extensively by
health care decision makers. Although software routines exist for conducting
NMA, they require considerable statistical programming expertise to use,
which limits the number of researchers able to conduct such analyses.
Objectives: To develop a web‐based tool allowing users with only standard
internet browser software to be able to conduct NMAs using an intuitive “point
and click” interface and present the results using visual plots.
Methods: Using the existing netmeta and Shiny packages for R to conduct
the analyses, and to develop the user interface, we created the MetaInsight tool
which is freely available to use via the web.
Results: A package was created for conducting NMA which satisfied our
objectives, and this is described, and its application demonstrated, using an
illustrative example.
Conclusions: We believe that many researchers will find our package helpful
for facilitating NMA as well as allowing decision makers to scrutinize presented
results visually and in real time. This will impact on the relevance of statistical
analyses for health care decision making and sustainably increase capacity by
empowering informed nonspecialists to be able to conduct more clinically rel-
evant reviews. It is also hoped that others will be inspired to create similar tools
for other advanced specialist analyses methods using the freely available tech-
nologies we have adopted.1 | INTRODUCTION
In this digital age where the quantity and complexity of
data is rapidly expanding, and, in response, statistical
analyses are increasing in complexity and becoming more
specialist, there is a growing need for bespoke tools that- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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©facilitate the implementation and understanding of differ-
ent analysis types. This is to ensure that researchers—
other than statistical experts—are still fully engaged with
state‐of‐the‐art approaches to data analysis.
In this paper, we describe and demonstrate one such
tool—MetaInsight—we developed for network meta‐wileyonlinelibrary.com/journal/jrsm 1
HIGHLIGHTS
• A new tool that is freely available and
conducts NMA via the web requiring no
specialist software for the user to install but
leveraging established analysis routines.
• The tool is interactive and uses an intuitive
“point and click” interface, which can also
2 OWEN ET AL.analysis (NMA), which we believe meets several unmet
needs. This tool is web‐based, freely available (https://
crsu.shinyapps.io/metainsightc), and runs on all modern
internet browser applications. We encourage the reader
to load and explore this tool (on a PC, tablet, or mobile
phone) in conjunction with reading the remainder of this
article.
The primary aim of this paper is to describe this tool
and demonstrate its capabilities which include:carry out sensitivity analyses on existing
NMAs in real time to help decision makers
scrutinize the robustness of analysis findings.
• The tool was created using free, recently
developed software, and we encourage others
to generate similar tools using it for their
areas of analysis expertise, particularly to
increase the capacity of complex and
specialist analysis approaches.
• It is hoped that this tool will increase the
relevance of published meta‐analyses and, in
the long term, contribute to improved health
care decision making as a result.i. Allowing the nonspecialist user to carry out a popu-
lar complex analysis method, NMA, in an interactive
environment within an internet browser window;
ii. Providing an interactive environment in which an
interested reader can further explore and scrutinize
a published NMA by excluding studies on a case‐
by‐case basis and, in doing so, check the robustness
of the analysis findings; and
iii. Providing a platform by which the user can easily
identify the impact of selecting different analysis
methods through modifying the tools “point and
click” options, since the tool gives immediate visual
feedback regarding how changing options or data
impacts the results.A secondary goal is to promote the underlying ideas that
drove the development of this specific tool and outline
how the ideas were realized in the finished product. It is
hoped that this will inspire and motivate others to
develop similar resources as we believe that their avail-
ability will make a broader array of analyses approaches
available to nonstatistical specialists and increase the rel-
evance of published meta‐analyses for health care deci-
sion making. While much of the software utilized in
developing the tool have only become available in recent
years, all technologies used are freely available, and
detailed knowledge of website development is not
required to use them.
In the remainder of the paper, we briefly outline what
NMA is and why it is an important methodology. Then,
we explain why the tool is needed, underpinned by our
experiences in developing, using, and teaching NMA
methodology. We then provide a jargon‐free overview of
the process and technologies used to develop the tool,
followed by an outline of the scope of what the tool does
and why it does it, illustrated with an example and figures
taken directly from the tool. The code used to create the
tool is also available in a technical specification document
provided in Data S1 Supporting Information —this illu-
minates its capabilities and presents our vision of what
accessible specialized data analysis tools should look like.A discussion, elaborating on important issues this work
has raised, concludes the paper.2 | WHAT IS NETWORK META ‐
ANALYSIS?
Meta‐analyses are established as a key component of the
evaluation of medical interventions in terms of clinical
effectiveness and cost effectiveness and as such are at
the forefront of health care decision making.1 Pairwise
meta‐analyses compare two interventions combining data
from multiple head‐to‐head trials to obtain an overall
summary effect size and its relative uncertainty. Network
meta‐analysis (NMA) extends the pairwise approach with
the aim to evaluate multiple interventions that may, or
may not, have been directly compared in the trials.2-4 In
doing so, this approach combines trials making different
intervention comparisons, which together form a con-
nected network of evidence (eg, Figure 1), to obtain rela-
tive treatment effects for all interventions compared with
one another. In recent years, NMA methods have been
widely adopted since they are able to answer the ques-
tions of clinical relevance such as, “which intervention
is the ‘best’ overall?” Network meta‐analyses are regularly
published in high‐quality medical journals, as well as
FIGURE 1 Network plot illustrating the network of treatment comparisons [Colour figure can be viewed at wileyonlinelibrary.com]
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ment decision bodies such as NICE.3 | WHY IS THERE A NEED FOR
THIS TOOL?
Currently, much of the software developed and used to
implement NMA analyses requires knowledge of special-
ist statistical packages such as WinBUGS5 and R,6 and
the output from such analyses can be extensive and com-
plex. While it could be argued that, ideally, a statistician
should always be involved in conducting a meta‐analysis,
in reality, many groups who carry out systematic reviews
containing meta‐analyses, including those within the
Cochrane Collaboration, do not have the resources avail-
able for this to always be possible. Through teaching
many NMA courses and supporting NIHR‐funded
reviews, as part of the Complex Review Support Unit
(CRSU), we have identified software as a barrier to
greater adoption of the methods, and the need for resultsto be presented in more intuitive and user‐friendly ways
to facilitate interpretation of results. This was the primary
motivator for the development of the tool: to enable us to
sustainably increase capacity by empowering informed
nonspecialists to be able to conduct more clinically rele-
vant reviews.
A further prior experience, which shaped the develop-
ment of this tool, was through our research in collabora-
tion with NICE, exploring how the health technology
assessment decision‐making process could be improved.
As a result of this collaboration, we built the Transparent
interactive decision interrogator (TIDI), which allowed us
to perform sensitivity analyses in real time in technology
appraisal committees.7 Although a success, creation of the
tool was complex, lengthy, and necessarily bespoke to a
specific topic due to the technology limitations at the
time. This tool motivated the development of MetaInsight,
which focuses specifically on evidence syntheses with the
advantage that MetaInsight is generalizable, allowing
users to input their own data, and allows decision makers
to perform sensitivity analyses in real time in technology
4 OWEN ET AL.appraisal meetings. A meta‐analysis should be seen as a
lens through which to examine the current evidence
rather than provide a totally objective “beyond criticism”
result.8 We hope that MetaInsight allows users to explore
this notion by easily changing basic NMA options, and
excluding studies on a case‐by‐case basis to explore the
robustness of results.
A final motivation was that, while we would consider
ourselves to be experts in NMA methods, this does not
mean that we would not appreciate a tool to facilitate
the analysis ourselves(!) While packages such as R cur-
rently have tremendous support for the gamut of statisti-
cal methods developed, the user interfaces for such
behemoths seem relatively neglected doing little to
encourage wider uptake.4 | HOW THE TOOL WAS CREATED
We used existing technologies as much as possible to
achieve our goals. Routines for conducting NMA in the
statistical package R have reached a level of maturity
and been peer reviewed.9 It seemed logical to utilize the
frequentist versions of these as the analysis “heart” of
the tool as implemented by the package netmeta.10 A
powerful package called Shiny11 has been recently
developed which enables web‐based user interfaces to be
developed to interact with R, and this was used to provide
the framework required for the tool. Although R is used
as the “backbone” for the tool, it is accessed “behind the
scenes” by the tool on the webserver so the user does
not need to install it (or any other software beyond a
web browser) on their device.5 | THE METAINSIGHT TOOL
The application can be accessed via the following URL
https://crsu.shinyapps.io/metainsightc with full R code
given in the web appendix.
The tool can interactively conduct NMA for both
binary and continuous outcomes for fixed and random
effects models12 and facilitates sensitivity analyses via
the inclusion and exclusion of studies. Note that, since
standard pairwise meta‐analysis can be seen as a special
case of NMA, the tool can also be used to conduct stan-
dard meta‐analysis.
The tool contains a feature for the users to upload
their own datasets into a webpage. Beyond this,
operation of the tool is via a “point and click” interface
via mouse/touchscreen. Graphical representations of the
treatment network and various aspects of the results are
provided. Any analyses/graphics produced can be saved
in pdf format. The box illustrates typical usage of theapp using an illustrative example dataset of
pharmacological interventions for the treatment of
obesity.136 | ILLUSTRATIVE EXAMPLE OF
THE USE OF THE METAINSIGHT
TOOL APPLIED TO A MIXED
TREATMENT COMPARISON OF
PHARMACOLOGICAL INTERVEN-
TIONS FOR THE TREATMENT OF
OBESITY
The example dataset evaluated change from baseline in
body mass index (BMI) for anti‐obesity interventions.13
There were six interventions of interest—placebo, orlistat,
sibutramine, metformin, orlistat + sibutramine, and
rimonbant—that were evaluated in various combinations
across 24 studies. Twenty of these studies were two‐arm
trials, three studies were three‐arm trials, and one study
was a four‐arm trial. A network plot of all studies is given
in (Figure 1). All studies reported estimates of mean dif-
ference from baseline in BMI, together with its corre-
sponding uncertainty.
Step 1). Input data
The MetaInsight tool has a specific data entry page under
the Load Data tab for each outcome type (continuous or
binary)—both initially contain example data, together
with their associated results, for illustration, didactic,
and exploration purposes. Users can import their data
easily by uploading a comma delimited (.csv) file in either
long or wide format. In this example, we have continuous
data (ie, outcome is change from baseline in BMI), and
therefore we need to input data on study ID (as sequential
and numerical code), study name, and treatment code (as
sequential and numerical code), the number of partici-
pants, the mean treatment effects, and corresponding
standard deviations for each arm of the study. Users
may enter their own text label for each intervention by
either copying‐and‐pasting from Microsoft Excel, or via
any tab separated file. These text labels will appear in
data and outputs of results. Users are reminded to keep
labels short to allow for clear displays on visual outputs.
An example of long format data entry is given in
Figure 2.
Step 2). Choose NMA options data type and analysis
Having input your data, the next step is to select the out-
come relevant for your data type under the Data Analysis
tab. In this example, we have continuous data, and our
FIGURE 2 Screenshot of the data entry for continuous data with preloaded example data in long format [Colour figure can be viewed at
wileyonlinelibrary.com]
OWEN ET AL. 5outcome of interest is the mean difference in BMI. For the
treatment rankings, the user must specify whether
smaller outcome values are desirable or undesirable. In
this example, as the outcome is change in BMI, smaller
(more negative) values indicate a larger change in BMI
and thus more effective treatments, and so we select
desirable. Finally, the type of NMA model to fit to the
data is selected—fixed or random effects12 (Figure 3).FIGURE 3 Screenshot of NMA options for continuous dataStep 3). Visualize data and results
One of the key features of the application is the visual-
ization of data and NMA results. The visual displays are
divided in to two subtabs: Data summary and
Frequentist NMA; each with their own subtabs
including: Study results, Network plot, Forest plot, Com-
parison of all treatment pairs, and Inconsistency.
Step 4). Study Results
The most widely used plot in meta‐analysis is a forest
plot which graphically displays the results from
individual studies included in the meta‐analysis plot-
ted on a common scale, in this example mean differ-
ence (Figure 4). This plot provides a visual display
of the study specific data grouped by each pairwise
treatment comparison allowing the user to visually
examine the degree of heterogeneity between studies
and identify any potentially outlying studies that the
user may wish to examine further/exclude from the
analysis as part of the sensitivity analysis (Step 4
below).Step 5). Network Plot
Network plots provide a visual display of the network of
evidence showing where interventions have been com-
pared in head‐to‐head trials, and importantly whether
FIGURE 4 Forest plot of individual study results grouped by treatment comparison. The measure of effect is mean difference with
corresponding 95% confidence intervals [Colour figure can be viewed at wileyonlinelibrary.com]
6 OWEN ET AL.there is a connected network of evidence, an essential
requirement for NMA. The tool produces a network plot
where each node on the plot represents an individual
intervention with connecting lines between nodes indi-
cating where one or more of the trials have evaluated
both interventions on a head‐to‐head basis (Figure 1).
The number of trials making each comparison is
displayed on each line.10Step 6). Forest Plot
In the interest of space and ease of interpretation, the tool
uses a succinct and easily interpretable approach imple-
mented within the netmeta package to display key
results.10 These plots present the pooled effect estimates,
and their associated uncertainty, for all interventions
compared with the reference treatment (coded as treat-
ment 1 in the data entry page—placebo in this example).
FIGURE 5 Forest plot [Colour figure can be viewed at wileyonlinelibrary.com]
OWEN ET AL. 7The comparison plot also displays key information such
as the between‐study standard deviation (indicating how
much heterogeneity there is), the number of studies,
and the number of treatments in the analysis. The results
for this example are displayed in Figure 5 and show that
rimonbant is likely to be the most effective treatment;
that is, in relation to placebo (the reference treatment),
rimonbant appeared to decrease BMI by approximately
−3.76 kg/m2 (95%CI: −5.52, −1.99).
Step 7). Comparison of all treatment pairs
Comparison plots, or league tables, provide all pairwise
comparisons in a NMA. Above the leading diagonal, in
the upper triangle, are the treatment comparisons
obtained from pairwise meta‐analyses. These are calcu-
lated as the treatment in the column versus the treat-
ment in the row and presented as point estimates
together with corresponding 95% confidence intervals.
Below the leading diagonal, in the lower triangle, are
the treatment comparisons obtained from the NMA.These are calculated as the treatment in the row versus
the treatment in the column and presented as point esti-
mates and corresponding 95% confidence intervals. The
interventions are ordered from the most effective inter-
vention to the least effective intervention along the lead-
ing diagonal (Figure 6).
Step 8). Inconsistency
Consistencies between treatment effect estimates
obtained from direct and indirect information are crucial
for assumptions underpinning NMA to hold. Agreement
between direct and indirect effect estimates can serve as
a check for consistency of NMAs.14 The MetaInsight tool
uses results obtained from the netmeta package10 to dis-
play the number of studies directly comparing treatments
of interest, NMA treatment effect estimates, treatment
effect estimates obtained from direct (ie, head to head)
comparisons, and treatment effect estimates obtained
from indirect information. For treatments that belong to
a closed loop in the network of evidence (ie, there exists
FIGURE 7 Assessment of inconsistency [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 6 Comparison plot [Colour figure can be viewed at wileyonlinelibrary.com]
8 OWEN ET AL.both direct and indirect information), the difference
between the direct and indirect estimates is calculated
together with the lower and upper limit of the 95% confi-
dence interval. Differences between direct and indirect
information are further quantified using P values where
a low P value can be used to indicate conflicting evidence
unlikely to be attributable to chance alone. In the exam-
ple dataset (Figure 7), there does not appear to be any
important estimated differences between direct and indi-
rect information.
Step 9). Perform sensitivity analysis
The influence of the different studies on the NMA
results can be investigated through sensitivity analysis.
For example, an analyst/clinician may want to explore
the impact on the results of excluding a less rigorous,poorer quality study (ies) to assess the robustness of
the analysis. As with all sensitivity analyses, there
should be a clear rationale for including/excluding stud-
ies in a NMA and a description of included/excluded
studies should be reported.1 Studies can easily be
excluded from the analysis using a simple checkbox
interface (Figure 8). The user can choose to exclude
one or more studies, and the NMA will be updated
and displayed alongside the complete case analysis
which remains visible to facilitate comparison. For illus-
trative purposes only, in this particular example, we
have chosen to exclude three studies (Kaya 2004,
Kiortsis 2008, Sathuapalan 2008).
The tool displays the network plot based on all stud-
ies entered into the tool (Figure 9A) next to the network
excluding selected studies (Figure 9B). If, by excluding
studies in the sensitivity analysis, an intervention is no
FIGURE 8 Screenshot of the checkbox
input for sensitivity analyses
FIGURE 9 Network plots illustrating the network of treatment comparisons after excluding studies to the left and the network plot
including all studies to the right [Colour figure can be viewed at wileyonlinelibrary.com]
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FIGURE 10 Forest plot [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 11 Comparison plot [Colour figure can be viewed at wileyonlinelibrary.com]
10 OWEN ET AL.longer connected to the network of evidence, eg,
Rimonbant in Figure 9, then the disconnected interven-
tion will disappear from the network plot.1
Similarly, summary forest plots (together with the
number of studies included, number of treatments, and
the estimated between‐study standard deviation) and
comparison plots can be displayed for all studies
(Figures 10A and 11A, respectively) and with
selected studies excluded (Figures 10B and 11B,
respectively).Visual inspection of study results and assessment of
inconsistency between direct and indirect evidence could
also be evaluated after selecting studies to exclude
whereby the plots will automatically update.Step 10). Output results
The user has the option to download results as a portable
document format (PDF), portable network graphic
OWEN ET AL. 11(PNG), or for study results, a scalar vector graphic (SVG).
The ability to output results allows the user to include the
produced figures directly in their NMA report.7 | DISCUSSION
This paper has presented a newly developed tool for
NMA, which makes conducting this popular analysis
available to a much wider audience than those who can
use the existing code‐based approaches. In addition to
researchers, we believe that the tool will be of interest
to decision makers and students/educators as we have
indicated throughout the paper.
MetaInsight allows both technical and nontechnical
audiences to easily implement NMA and further explore
data using user‐friendly interfaces. As with all statistical
analyses, the ease of use of this tool may open the possi-
bility of the noninformed user to misinterpret results. In
this instance, we encourage the user to seek advice from
technical experts. However, MetaInsight has been
designed in such a way to limit human error, and conse-
quently, the optional features implemented in
MetaInsight are limited, such as fixed variables and vari-
able names for data entry, numeric coding for treatments
with the reference treatment in the network coded as 1,
and restricting the number of arms in a study to a maxi-
mum of 6. A further limitation of the tool includes the
inability to exclude studies based on a particular charac-
teristic, eg, studies with a high risk of bias. Alternatively,
the tool offers the ability to exclude studies on a case‐by‐
case basis. For users wishing to fit more complex NMA
models, including Bayesian NMA, and network meta‐
regression models, for complex clinical scenarios, we
encourage nontechnical users to consult with technical
experts. Technical users may wish to make use of the full
flexibility, modeling options, and output offered in the
netmeta package10 as well as other packages such as
metafor 15 in R, network16 and network_graphs17
in Stata, SAS, JAGS, WinBUGS, OpenBUGS, and Stan.18
The tool's framework leverages the power of the Shiny
web interface for R, without which it would have been
much more difficult for us to create. We believe the Shiny
package has enormous untapped potential for use within
medical research as it can connect all R analysis routines
to the internet while circumventing the need to be fluent
in the web development code languages HTM, CSS, and
Javascript, as well as having web server programming
proficiency.
Recently, others have also built web‐based applications
for conducting systematic reviews, and we highlight the
similarities and differences of these to MetaInsight below.
Meta‐analysis via Shiny (MAVIS)19 conducts pairwisemeta‐analyses, allowing users to input their own data and
produce numerical and graphical outputs. Hence, this tool
is similar in construction and functionality to ours, but is
limited to only pairwise meta‐analysis and relies on more
standard text‐based output formats. MetaBUS20 is an ambi-
tious cloud‐based platform that semi‐automates the litera-
ture searching process by searching its own curated
database of social science papers and associated results on
a user‐requested topic and combines the findings in a
pairwise meta‐analysis (also using R and Shiny “under
the hood”). Hence, its major innovation is its ability to
scrutinize a database and compile results data without
the need for the user to do the preliminary stages of the
analysis. Hence, while similar in spirit, both these apps
have different scopes and remit to ours and neither can
conduct NMA, our primary focus.
The Aggregate Data Drug Information System
(ADDIS)21 and NetMetaXL22 share the aim ofMetaInsight
to increase capacity of network meta‐analyses for non-
technical users. ADDIS21 enables a semi‐automated con-
struction of network meta‐analyses using a standalone
“point and click” software package to perform Bayesian
network meta‐analyses. NetMetaXL22 is based entirely
within Microsoft Excel and provides a user‐friendly inter-
face for users to perform Bayesian network meta‐analyses
using WinBUGS. Both of these tools allow users to per-
form complex Bayesian network meta‐analyses and pro-
vide all outputs in a visually appealing way. MetaInsight
offers a frequentist alternative using a user‐friendly inter-
face based entirely on standard internet browsers and
provides users with the opportunity to easily assess the
robustness of results through the opportunity to perform
sensitivity analyses using the “point and click” interactive
interface. Another useful tool for facilitating the evalua-
tion of NMA results is the freely available web‐based tool,
CINeMA.23 CINeMA provides an interactive platform to
assess the confidence in NMA results. Similarly to
MetaInsight, CINeMA offers interactive network plots,
league tables, and assessment of inconsistency. Further
to this, CINeMA allows users to evaluate the contribution
of individual studies on NMA estimates, assess heteroge-
neity in the network, and assess the overall risk of bias
for contributing studies. Using packages such as CIN-
eMA, we encourage users to explore the confidence in
NMA results and contributions of individual studies,
which could potentially inform sensitivity analyses using
MetaInsight's interactive platform.
There is much related further work possible in the cre-
ation of tools such as ours. Even within evidence synthe-
sis, we have identified a need for, and started developing,
a tool to conduct meta‐analysis of diagnostic test data.
There are also many possible extensions to the existing
tool, including the option to undertake analyses in a
12 OWEN ET AL.Bayesian framework, and the ability to include study‐
level covariates.24 We are also looking to extend our pre-
vious work on web‐based visualization in three dimen-
sions for network‐meta‐analysis25 (a coding expert
programmed this app, but a similar tool would be possible
with Shiny) to further develop the graphical outputs of
this tool.
We are also exploring the possibility of being able to
create and re‐publish the tool around a particular
dataset that is “hard wired” into it. For example, when
an NMA is published in a journal, our interactive front
end to the associated dataset could be supplied as a
“web extra” that could allow readers of the article the
opportunity to explore the dataset and scrutinize the
robustness of the analyses very quickly and easily. We
think this is especially relevant for meta‐analysis as
there are invariably subjective decisions made regarding
the relevance of evidence in a systematic review, as well
as end users wanting to ask subtle variations on the
primary question of the review (eg, they may seek to
explore a more targeted question relating to a subgroup
of patients etc.).ACKNOWLEDGEMENTS
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